Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives
| Autor: | Mou-Ze Liu, Jian-Quan Luo, Yi-Ping Liu, Hai-Yan He, Zhangren Chen, Wei Zhang, Hong-Hao Zhou, Da-Xiong Xiang, Fa-Zhong He |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug medicine.medical_treatment media_common.quotation_subject 030204 cardiovascular system & hematology Bioinformatics 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Diabetes mellitus Drug Discovery medicine Diabetes Mellitus Humans Hypoglycemic Agents Antipsychotic media_common business.industry Organic Chemistry Precision medicine medicine.disease Calcineurin 030104 developmental biology Pharmacogenetics Pharmacodynamics Pharmacogenomics Hyperglycemia Molecular Medicine business Antipsychotic Agents |
| Zdroj: | Archives of pharmacal research. 41(7) |
| ISSN: | 1976-3786 |
| Popis: | Drug-induced diabetes is widely reported in clinical conditions, and it is becoming a global issue because of its potential to increase the risk of severe cardiovascular complications. However, which drug mechanisms exert their diabetogenic effects and why the effects present significant inter-individual differences remain largely unknown. Pharmacogenomics, which is the study of how genomic variation influences drug responses, provides an explanation for individual differences in drug-induced diabetes. We highlight that pharmacogenomics can be involved in regulating the expression of genes in signaling pathways related to the pharmacokinetics or pharmacodynamics of drugs or the pathogenesis of diabetes, contributing to the differences in drug-induced glucose impairment. The pharmacogenomics studies of the major diabetogenic drugs are reviewed, including calcineurin inhibitors, antipsychotics, hormones, and antihypertensive drugs. We intend to elucidate the genetic basis of drug-induced diabetes and pave the way for the precise use of these drugs in the clinic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink